Scalp Exosomes

Exosome science began in oncology and regenerative medicine, where exosomes' role as cellular communication vehicles — carrying molecular cargo between cells — was identified as a therapeutic target. The application to scalp and hair science is newer, but the mechanism is the same: exosomes carry biological information that directs cellular behaviour.

What makes exosomes particularly interesting for hair loss is the microbiome angle. The scalp microbiome in individuals with healthy, dense hair differs significantly from those experiencing hair loss — not just in which species are present, but in the signalling environment those species create. Healthy scalps show higher abundance of Lactobacillus-family species, which produce lactic acid (maintaining an acidic, protective pH), short-chain fatty acids (anti-inflammatory), and antimicrobial compounds (suppressing Malassezia and Staphylococcus pathogenic strains).

Topically-applied exosomes — particularly those derived from young cell cultures — deliver signalling molecules that support the proliferation of these beneficial microbiome species, helping to restore the scalp to a "younger" microbial state. This is distinct from prebiotic and probiotic scalp approaches, which add specific bacterial strains directly; exosomes work at the signalling level, creating an environment where beneficial species can re-establish themselves.

The combination of exosomes with DHT-inhibiting actives (topical caffeine) addresses hair loss from two complementary axes: the hormonal pathway (DHT → follicle miniaturisation) and the microbiome pathway (dysbiosis → inflammatory follicle environment → telogen effluvium). Neither pathway alone explains all hair loss — which is why single-mechanism interventions underperform for most patients.

Exosome science in scalp care is still in its early clinical phase — most published studies are in vitro or small-cohort. This is the honest frontier of the field: the mechanism is biologically well-grounded, the early results are encouraging, but large-scale RCTs are not yet published. For consumers, this means exosome products should be evaluated as adjunctive to proven actives (caffeine, minoxidil, botanicals), not as standalone solutions.